Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988
- 30 June 1986
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 39 (2) , 111-117
- https://doi.org/10.1016/0024-3205(86)90444-3
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the plateletBiochemical Pharmacology, 1985
- Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. studies with paf-receptor antagonist kadsurenoneBiochemical and Biophysical Research Communications, 1985
- Is platelet activating factor (PAF) a mediator of endotoxin shock?European Journal of Pharmacology, 1985
- Inhibition of binding of the platelet-activating factor AGEPC to platelets by the AGEPC analog rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate (CV-3988)Biochemical and Biophysical Research Communications, 1985
- Effect of 1-alkyl-2-acetyl--glycero-3-phosphorylcholine inhibitor on the reduction of one-kidney, one clip hypertension after unclipping in the ratLife Sciences, 1984
- Syntheses and biological activities of N-alkyl- and N-alkenylcarbamoyl phospholipids.CHEMICAL & PHARMACEUTICAL BULLETIN, 1984
- CV-3988 - A specific antagonist of platelet activating factor (PAF)Life Sciences, 1983
- BACKGROUND AND PRESENT STATUS OF RESEARCH ON PLATELET‐ACTIVATING FACTOR (PAF‐ACETHER)Annals of the New York Academy of Sciences, 1981
- LEUKOCYTE-DEPENDENT HISTAMINE RELEASE FROM RABBIT PLATELETSThe Journal of Experimental Medicine, 1972
- A STUDY OF THE COAGULATION DEFECT IN HEMOPHILIA AND IN JAUNDICE.*The Lancet Healthy Longevity, 1935